Comment on Oracle to buy Phase Forward for $685 million

Boston Globe: Local
Fri, 04/16/2010 - 5:08am

Oracle to buy Phase Forward for $685 million

Oracle is buying Phase Forward, a maker of software used to manage clinical drug trials, for $17 per share in cash, or $685 million.